June 2020 Clinical Watch Newsletter

July 8, 2020

In this issue of Clinical Watch, we discuss nitrosamine impurities found in widely used medications and suggest prior authorization criteria for a new treatment for heavy menstrual bleeding due to uterine fibroids. Lastly, we review claims data to identify the most frequently used contraceptive formulations.

For more information about a specific topic, please contact Janelle Sheen or Karen Powell. Be sure to stay tuned for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacysolutions.

Previous Article
Five elements to consider when implementing an Electronic Visit Verification (EVV) Program
Five elements to consider when implementing an Electronic Visit Verification (EVV) Program

Conduent can help states to swiftly and seamlessly implement their Electronic Visit Verification EVV Progr...

Next Flipbook
May 2020 Clinical Watch Newsletter
May 2020 Clinical Watch Newsletter

In this issue of Clinical Watch, we highlight the use of diabetes drugs in the treatment of heart failure a...

Explore our Clinical Watch Newsletter

Learn More